We are committed to our vision of transforming lives and making hope a reality for patients with severe genetic and rare diseases and with cancer..In addition, we are combining several strategic functions under Jeff s leadership to maintain our strategic focus in a rapidly evolving field. As a result, Jim has .Derek Adams, Ph.D., joined us in March as our chief technology and manufacturing officer. Prior to joining bluebird, Derek was the senior vice president of .Nick Leschly has served as our chief bluebird since September . For over years, Mr. Vachon held a variety of leadership positions across the General .
Related posts to leadership bluebird bio
He served as interim chief medical officer of bluebird bio in and previously served on the board of directors of the American Society for Human Genetics. Phil is currently a trustee of Cornell University and is a founding fellow of the American College of Medical Genetics..
You are now leaving Links to sites outside of this website are provided as a resource to the viewer. bluebird bio accepts no responsibility for the content of .
About the bluebird bio Celgene Collaboration. bluebird bio and Celgene are collaborating to develop CAR T cell therapies targeting BCMA. The collaboration’s lead oncology program, bb, is currently being stu.d for the treatment of relapsed and refractory multiple myeloma..
View Mark Battaglini’s profile on LinkedIn, the world’s largest professional community. Global Government Affairs and Public Policy for Bluebird Bio since December, . leadership with .